ABSTRACT Previous studies have shown that some patients with chronic obstructive lung disease and hypercapnia will respond to medroxyprogesterone with improvement in arterial blood gases. The exact mechanism of this effect is unclear but it is presumed to be a result of ventilatory stimulation. To determine whether the ability to correct arterial blood gas abnormalities by voluntary hyperventilation would predict a subsequent favourable response to progesterone, we studied 11
Chronic hypercapnia may result from conditions that impair the function of the lungs or chest bellows, or from primary disorders of respiratory control even when mechanical lung function is normal' 3 Parenteral and oral progesterone treatment have been found to be effective respiratory stimulants in conditions characterised by abnormal respiratory control, such as the obesity-hypoventilation syndrome,4 s as well as in some patients with chronic obstructive lung disease.6-10 The ability to correct raised carbon diox-ide tension (Paco2) with voluntary hyperventilation has been used in diagnosing the obesityhypoventilation syndrome and for predicting a successful outcome with progesterone treatment.245 11 One study suggested that response to chronic progesterone treatment among patients with chronic obstructive lung disease could be predicted from voluntary hyperventilation. 8 The object of the present study was to compare the effects of medroxyprogesterone on arterial blood gas tensions in patients with chronic obstructive lung disease who could and could not reduce their PaCO2 by voluntary hyperventilation.
Methods
Twenty subjects with chronic airflow obstruction and 616
Oral progesterone treatment in chronic obstructive lung disease 
Results
Eleven subjects met all of the criteria and were able to complete the protocol as described. The In essence, correctors were characterised by a moderate degree of chronic airflow obstruction, appreciable resting hypoxia and hypercapnia, and the ability to normalise their arterial blood gas tensions during voluntary hyperventilation. The noncorrectors had more severe chronic airflow obstruction with a similar degree of resting hypoxia and hypercapnia but were unable to alter their blood gases significantly during voluntary hyperventilation.
There were no significant changes in spirometric values or lung volumes while the subjects were taking medroxyprogesterone acetate or placebo. While taking medroxyprogesterone acetate, but not placebo, both groups had a significantly lower Paco2 and a significantly higher Pao2 (table 3) . The response to medroxyprogesterone acetate was similar in the two groups of patients, who had almost identical mean values of Pao2 and Paco2 while taking placebo and medroxyprogesterone acetate. The changes in Pao2 are potentially important because they occurred on the steep portion of the oxyhaemoglobin dissociation curve, so that they were associated with substantial changes in oxygen saturation.
Of further interest is the fact that two correctors who had polycthaemia (haemoglobin concentrations l9 5 and 18-8 g/dl) showed falls in haemoglobin concentration (to 15 
Discussion
Progesterone is known to stimulate ventilation in normal subjects, in patients with the obesityhypoventilation syndrome,4 5 and in some patients with chronic obstructive lung disease.6 -10 The new observation made in this study is the identification of a group of patients with chronic obstructive lung disease whose mechanical abnormality was sufficiently severe for them to be unable to correct their arterial blood gas tensions with voluntary hyperventilation but who did improve them with long term medroxyprogesterone acetate. This finding was unexpected and its explanation is not clear. Possibilities include (1) less carbon dioxide production with medroxyprogesterone than with voluntary hyperventilation and (2) a more efficient pattern of ventilation with medroxyprogesterone than with voluntary hyperventilation, for example, increased tidal volume rather than increased ventilatory rate. 8 Probably some patients with chronic obstructive lung disease and chronic hypercapnia, in addition to their mechanical limitation to ventilation, have an abnormal ventilatory drive that is not treated with standard medication. If some patients with chronic obstructive lung disease "won't breath" as opposed to "can't breathe," and if they could be detected and treated more effectively with a respiratory stimulant, this might considerably improve their condition.
For many years, clinicians have taken the patient's ability to improve or normalise his arterial blood gas tensions during voluntary hyperventilation to indicate a defect of central respiratory control. In our study patients who could significantly reduce their raised Paco2 by voluntary hyperventilation had less severe chronic airflow obstruction than those who could not. This is consistent with findings in previous studies.2 8 9 13 Otis has explained the inability of patients with severe airflow obstruction to reduce their Paco2 during hyperventilation in terms of the associated increase in the work of breathing and carbon dioxide production that cannot be effectively eliminated by the increased ventilation.'4 A further consideration is the pattern of ventilation, since increasing minute ventilation via an increased tidal volume may be more efficient than by increasing the
